国产西罗莫司洗脱支架治疗急性心肌梗死的安全性和有效性

Efficacy and safety of domestic sirolimus-eluting coronary stent in the treatment of myocardial infarction

目的:评估国产西罗莫司药物洗脱支架Firebird2TM治疗急性心肌梗死的安全性和有效性。方法:连续入选2010年9月至2011年12月因急性心肌梗死在我院行介入治疗的120例患者。观察并分析所有患者冠状动脉的靶血管特点、支架植入情况、住院期间和支架植入术后6个月的主要心脏不良事件(MACE,包括死亡、再发心梗、靶血管的再次血运重建)发生率和支架内血栓发生率。结果:120例急性心肌梗死患者靶血管共植入支架152枚,术后即刻TIMI3级获得率95.8%,住院期间死亡1例。术后6个月临床随访总MACE事件的发生率为5%,死亡2例,靶血管的再次血运重建4例,无再发心梗和支架内血栓发生。结论:国产西罗莫司洗脱支架Firebird2TM对急性心肌梗死患者具有良好的安全性和疗效。

Objective： To evaluate the safety and efficacy of domestic sirolimus-eluting stent （Firebird2^TM stent） in treating patients with myocardial infarction （MI）. Methods： A total of 120 consecutive myocardial infarction patients undergoing PCI with Firebird2TM sirolimus-eluting stent implantation between September 2009 and December 2011 were included. We reviewed the baseline clinical,angiographic characteristics and followed up all the patients by telephone or clinical visits for 6 months. The primary end points was composite major adverse cardiac events （MACE） including death, non-fatal MI,and target vessel revascularization （TVR）. Results：Overall, 152 Firebird2TM stents were implanted successfully in 120 patients. The rate of TIMI 3 flow after PCI was 95.8%. The 6-month rate of MACE was 5 %, including 2 deaths, 4 TVR. There were no non-fatal MI and stent thrombosis （ST）. Conclusion：Firebird2TM sirolimus-eluting stent is effective and safe in the treatment of patients with myocardial infarction.